Abstract: Disclosed herein are compositions including an aptamer bound to a complex, wherein the complex comprises at least two polypeptides. Also disclosed are methods of quantifying a fraction of PD1 occupied by PDL1 or a fraction of PDL1 occupied by PD1 in a sample, and methods of isolating complexes using aptamers that are capable of binding to the complex.

Abstract: Disclosed herein are compositions including an aptamer bound to a complex, wherein the complex comprises at least two polypeptides. Accordingly, methods of using the aptamers and making the aptamers are also disclosed.

Abstract: Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Abstract: Disclosed are compositions, kits, and methods for treating cancer in a subject in need thereof. The compositions, kits, and methods may be used to treat a tumor in a subject in situ. The compositions, kits, and methods comprise or utilize cytotoxic particles, immune checkpoint inhibitors, and/or T-cell stimulatory agents.

Abstract: Disclosed herein are compositions including an aptamer bound to a complex, wherein the complex comprises at least two polypeptides. Accordingly, methods of using the aptamers and making the aptamers are also disclosed.

Abstract: Disclosed are compositions, kits, and methods for treating cancer in a subject in need thereof. The compositions, kits, and methods may be used to treat a tumor in a subject in situ. The compositions, kits, and methods comprise or utilize cytotoxic particles, immune checkpoint inhibitors, and/or T-cell stimulatory agents.

Abstract: A cable reinforced matrix to support a solar panel array comprising array bracing beams which define a perimeter including longitudinal array bracing beams and latitudinal array bracing beams with coupling apertures at various points along the latitudinal array bracing beams; cable couplings at opposite points along the latitudinal array bracing beams; cabling traversing the latitudinal array bracing beams; solar panels atop the cabling; longitudinal I-beams; latitudinal I-beams; interpanel I-beam(s); grommets along the cabling; grommet clips; grommet clip fasteners; panel fasteners; columns at either end of the longitudinal array bracing beams; a first cantilever support post extending from the column to the distal portion of the longitudinal array bracing beam; a second cantilever support post extending from the column to the proximal portion of the longitudinal array bracing beam; a footing at the bottom of each column; and dampening/stabilizing element(s) to mitigate vibration and uplift.

Abstract: The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.

Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.

Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.

Abstract: The present invention encompasses methods for inhibiting cancer, but in particular for inhibiting metastasis, by administering to a cancer patient an inhibitor of the complement cascade.

Abstract: The present invention encompasses methods for predicting metastasis in cancer by assessing the structure of the complement protein C1qA. The methods may encompass examining either protein or nucleic acids, and may further include making treatment decisions based on the predictive methods.

Abstract: The present invention involves the combined use of IL-21 and TLR agonists such as CpG oligonucleotides in the treatment of B cell cancers and B cell-related immune pathologies such as autoimmune diseases. In addition, it is demonstrated that human B cells produce and secrete varying amounts of Granzyme B in response to IL-21 depending on their activation state, and at the same order of magnitude as those secreted by cytotoxic T lymphocytes. In CpG ODN-treated B-CLL cells, Granzyme B secretion in response to IL-21 can be cytotoxic.

Abstract: Methods of reducing nonspecific binding of a fluorophore to cells expressing a Fc receptor, for example, CD64, is provided.

Abstract: The present invention encompasses methods for predicting metastasis in cancer by assessing the structure of the complement protein C1qA. The methods may encompass examining either protein or nucleic acids, and may further include making treatment decisions based on the predictive methods.

Abstract: The present invention relates to synergistic combinations of immunostimulatory CpG oligonucleotides and immunopotentiating cytokines. In particular, the invention relates to methods of stimulating an immune response using the synergistic combination of compounds and products related thereto.

Abstract: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful as a synthetic adjuvant.

Abstract: The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.

Abstract: Compositions comprising immunostimulatory oligonucleotides (CpG ODN) and FcR-directed immunotherapeutics are disclosed. Also disclosed are methods of using the compositions to enhance FcR-mediated antigen presentation, ADCC, and other FcR-mediated immune responses.

Abstract: The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.